  The epidemic of COVID-19 has caused an unpredictable and devastated disaster
to the public health in different territories around the world. Common
phenotypes include fever, cough, shortness of breath, and chills. With more
cases investigated, other clinical phenotypes are gradually recognized, for
example, loss of smell, and loss of tastes. Compared with discharged or cured
patients, severe or died patients often have one or more comorbidities, such as
hypertension, diabetes, and cardiovascular disease. In this study, we
systematically collected and analyzed COVID-19-related clinical phenotypes from
70 articles. The commonly occurring 17 phenotypes were classified into
different groups based on the Human Phenotype Ontology (HPO). Based on the HP
classification, we systematically analyze three nervous phenotypes (loss of
smell, loss of taste, and headache) and four abdominal phenotypes (nausea,
vomiting, abdominal pain, and diarrhea) identified in patients, and found that
patients from Europe and USA turned to have higher nervous phenotypes and
abdominal phenotypes than patients from Asia. A total of 23 comorbidities were
found to commonly exist among COVID-19 patients. Patients with these
comorbidities such as diabetes and kidney failure had worse outcomes compared
with those without these comorbidities.
